Clinical Trial Update: Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo [Phase 2]

View source ↗

Summary

Phase 2 trial update on afamelanotide in combination with NB-UVB for nonsegmental vitiligo; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• afamelanotide (Scenesse) (afamelanotide)

Snippet

Sponsor: Clinuvel Pharmaceuticals Limited | Conditions: Vitiligo | Phase 2 | Status: COMPLETED